We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

16 hedge funds and large institutions have $9.62M invested in NeuBase Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

762% more capital invested

Capital invested by funds: $1.12M → $9.62M (+$8.5M)

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

23% more funds holding

Funds holding: 13 → 16 (+3)

Holders
16
Holders Change
+3
Holders Change %
+23.08%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GC
Greenlight Capital
New York
+$7.59M
2
Renaissance Technologies
Renaissance Technologies
New York
+$216K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$71.6K
4
VF
Virtu Financial
New York
+$62.9K
5
HWA
Heritage Wealth Advisors
Virginia
+$54.3K

Top Sellers

Rank Fund Capital Flow
1
FIA
FNY Investment Advisers
New York
-$65.3K
2
MIG
Mariner Investment Group
New York
-$57K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
Greenlight Capital
New York
$7.68M +$7.59M +76,923 New
Renaissance Technologies
2
Renaissance Technologies
New York
$1.28M +$216K +2,185 +20%
Vanguard Group
3
Vanguard Group
Pennsylvania
$205K +$71.6K +725 +55%
BlackRock
4
BlackRock
New York
$104K – – –
FIA
5
FNY Investment Advisers
New York
$86K -$65.3K -661 -43%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$79K – – –
VF
7
Virtu Financial
New York
$64K +$62.9K +637 New
HWA
8
Heritage Wealth Advisors
Virginia
$54K +$54.3K +550 New
Morgan Stanley
9
Morgan Stanley
New York
$37K +$35.9K +364 +3,309%
UBS Group
10
UBS Group
Switzerland
$19K +$12.5K +127 +212%
LTFS
11
Ladenburg Thalmann Financial Services
Florida
$2K – – –
SSB
12
Sandy Spring Bank
Maryland
$2K – – –
CLOS
13
Compagnie Lombard Odier SCmA
Switzerland
$1K – – –
First Manhattan
14
First Manhattan
New York
$1K – – –
PA
15
Parallel Advisors
California
$1K +$592 +6 New
Bank of America
16
Bank of America
North Carolina
$1K +$691 +7 +700%
MIG
17
Mariner Investment Group
New York
– -$57K -833 Closed

NBSE Hedge Fund Activity: Q3 2019 in Review

16 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2019, worth a combined $9.62M — up 762% from $1.12M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new NBSE positions and 1 closed out — a net gain of 3 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Greenlight Capital, opening a new position worth an estimated $7.59M. The largest seller was FNY Investment Advisers, cutting an estimated $65.3K.

  • 16 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2019, up from 13 in Q2 2019.
  • Funds reported $9.62M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2019, up 762% quarter-over-quarter.
  • 4 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2019 and 1 closed out, a net change of +3 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2019 was Greenlight Capital, an estimated $7.59M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2019 was FNY Investment Advisers, an estimated $65.3K sold.

Based on aggregated 13F filings for Q3 2019.